Payment overview · 2025
General Payments
$406.87
21 reported records · 13 companies
Healthcare provider profile · identity verified
Mark David Friedman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOCA RATON, FL · NPI 1235109521
Verified facts
What the public records show
CMS Open Payments records show Mark David Friedman, MD received $406.87 in general payments during 2025 across 21 reported records.
Amgen Inc. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Entresto, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.43 | 17.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.27 | 15.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.25 | 14.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.35 | 12.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.07 | 6.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.24 | 6.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.97 | 4.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.15 | 4.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.40 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.83 | 4.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.26 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.36 | 3.5% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $13.29 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.87 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $49.35 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $13.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 27 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 157 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
101 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 422 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 74 |
| Alprazolam | Alprazolam | 233 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 55 |
| Sertraline Hcl | Sertraline Hcl | 177 | 44 |
| Ezetimibe | Ezetimibe | 164 | 52 |
| Irbesartan | Irbesartan | 160 | 42 |
| Eliquis | Apixaban | 157 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 38 |
| Famotidine | Famotidine | 135 | 43 |
| Simvastatin | Simvastatin | 127 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 32 |
| Methylprednisolone | Methylprednisolone | 117 | 90 |
| Ozempic | Semaglutide | 112 | 18 |
| Furosemide | Furosemide | 111 | 27 |
| Temazepam | Temazepam | 111 | 28 |
| Synthroid | Levothyroxine Sodium | 101 | 25 |
| Potassium Chloride | Potassium Chloride | 94 | 23 |
| Azithromycin | Azithromycin | 93 | 83 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 23 |
| Finasteride | Finasteride | 82 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 22 |
| Losartan Potassium | Losartan Potassium | 77 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 64 |
| Montelukast Sodium | Montelukast Sodium | 73 | 23 |
| Omeprazole | Omeprazole | 73 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 51 |
| Metformin Hcl | Metformin Hcl | 64 | 17 |
| Metformin Hcl Er | Metformin Hcl | 62 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 45 |
| Gabapentin | Gabapentin | 58 | 15 |
| Diazepam | Diazepam | 53 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Ondansetron Odt | Ondansetron | 50 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 50 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Livalo | Pitavastatin Calcium | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 47 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 16 |
| Glimepiride | Glimepiride | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 13 |
| Meloxicam | Meloxicam | 42 | 18 |
| Lisinopril | Lisinopril | 41 | 13 |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Multaq | Dronedarone Hcl | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | 11 |
| Ramipril | Ramipril | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 16 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 26 |
| Prednisone | Prednisone | 28 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 27 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 18 | 18 |
| Cefdinir | Cefdinir | 17 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Rybelsus | Semaglutide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.87 · 21 records | Amgen Inc. | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, GEMTESA, LEQVIO, Leqembi, MOUNJARO, OTEZLA, PREVNAR 20, PROLIA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, VYNDAQEL, Wegovy, XYOSTED, ZEPBOUND, Zypitamag | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error